These favorable effects, however, could be due, at least in part, also to other antitumor immunity-promoting effects that have been observed with CDK4/6 inhibitors such as increased production of type III interferons and enhanced tumor antigen presentation [126]. The gene discussed is CDK4; the disease is neoplasm.